×

We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Maplewood/Washington — US support for waiving intellectual property (IP) rights on Covid-19 vaccines could be a tactic to convince drugmakers to back less drastic steps such as sharing technology and expanding joint ventures to quickly boost global production, lawyers said on Thursday.

“I think the end result that most players are looking for here is not IP waiver in particular, it’s expanded global access to the vaccines,” said professor Lisa Ouellette of Stanford Law School...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now

Would you like to comment on this article?
Register (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.

Commenting is subject to our house rules.